Kumar Channaveerachari Naveen, Andrade Chittaranjan, Murthy Pratima
Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.
J Stud Alcohol Drugs. 2009 May;70(3):467-74. doi: 10.15288/jsad.2009.70.467.
For important reasons, lorazepam (Ativan) and chlordiazepoxide (Librium) are both popular treatments for alcohol-withdrawal syndrome. Nevertheless, there is little literature directly comparing the two drugs. A formal comparison is desirable because of pharmacokinetic and other differences that could affect safety and efficacy considerations relevant to practice in developing countries.
One hundred consecutive consenting male inpatients in a state of moderately severe, uncomplicated alcohol withdrawal at screening were randomized to receive either lorazepam (8 mg/day) or chlordiazepoxide (80 mg/day) with dosing down-titrated to zero in a fixed-dose schedule across 8 treatment days. Double-blind assessments of withdrawal-symptom severity and impairing adverse events were obtained during treatment and for 4 days afterward.
One chlordiazepoxide patient developed withdrawal delirium. Lorazepam and chlordiazepoxide showed similar efficacy in reducing symptoms of alcohol withdrawal as assessed using the revised Clinical Institute Withdrawal Assessment for Alcohol scale. During withdrawal, irritability and dizziness were more common with lorazepam, and palpitations were more common with chlordiazepoxide. No difficulties in drug discontinuation or differences in impairing adverse events were observed with either drug.
With the treatment schedule used in this study, lorazepam is as effective as the more traditional drug chlordiazepoxide in attenuating uncomplicated alcohol withdrawal. Lorazepam, therefore, could be used with confidence when liver disease or the inability to determine liver function status renders chlordiazepoxide therapy problematic. The absence of clinically significant withdrawal complications with lorazepam in this large study contrasts with findings from previously published studies and suggests that higher doses of lorazepam than those formerly used may be necessary during alcohol withdrawal.
出于重要原因,劳拉西泮(阿替凡)和氯氮卓(利眠宁)都是治疗酒精戒断综合征的常用药物。然而,直接比较这两种药物的文献很少。由于药代动力学和其他差异可能会影响与发展中国家实践相关的安全性和有效性考虑因素,因此进行正式比较是可取的。
100名在筛查时处于中度严重、无并发症酒精戒断状态且同意参与的男性住院患者被随机分配接受劳拉西泮(8毫克/天)或氯氮卓(80毫克/天)治疗,并按照固定剂量方案在8个治疗日内逐渐减量至零。在治疗期间及之后的4天内,对戒断症状严重程度和有害不良事件进行双盲评估。
一名氯氮卓患者出现戒断谵妄。使用修订后的酒精戒断临床研究所评估量表评估,劳拉西泮和氯氮卓在减轻酒精戒断症状方面显示出相似的疗效。在戒断期间,劳拉西泮组易怒和头晕更为常见,氯氮卓组心悸更为常见。两种药物在停药方面均未出现困难,在有害不良事件方面也未观察到差异。
采用本研究中的治疗方案,劳拉西泮在减轻无并发症酒精戒断方面与更传统的药物氯氮卓一样有效。因此,当肝病或无法确定肝功能状态使氯氮卓治疗出现问题时,可以放心使用劳拉西泮。在这项大型研究中,劳拉西泮未出现具有临床意义的戒断并发症,这与先前发表的研究结果形成对比,表明在酒精戒断期间可能需要比以前使用的剂量更高的劳拉西泮。